Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. 1989

K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
Department of Clinical Immunology and Biological Therapy, University of Texas M.D. Anderson Cancer Center, Houston 77030.

Twenty-seven patients with metastatic cancer were treated with a daily continuous intravenous (IV) infusion of recombinant human interleukin-2 (rhIL-2) along with daily intramuscular recombinant interferon-alpha-2a (rIFN-alpha-2a) 4 days per week for 4 weeks with repeated treatment after 2 to 4 weeks of rest. The maximum-tolerated dose (MTD) was 3 million U/m2/d of rhIL-2 with 5 to 10 million U/m2/d of rIFN-alpha-2a. The dose-limiting toxicities are moderate hypotension requiring low doses of pressors and chronic fatigue associated with decreased performance status. Other common side effects included fever, chills, fluid retention, nausea/vomiting, erythrodermia, weight loss, elevated liver transminase levels, anemia, thrombocytopenia, and CNS toxic effects. There were seven objective responses among 25 evaluable patients. Four major responses (one complete response and three partial responses) were observed among 10 patients with melanoma treated with the MTD level. These data suggest that for cancer patients, concomitant rhIL-2 and rIFN-alpha-2a therapy is tolerable and has manageable side effects. Further phase II studies will be needed to define the antitumor activity of this combination.

UI MeSH Term Description Entries
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005221 Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Lassitude
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias

Related Publications

K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
August 1990, Cancer,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
April 1993, Cancer,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
October 1991, Cancer,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
January 1991, Journal of acquired immune deficiency syndromes,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
December 1990, Journal of biological response modifiers,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
February 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
March 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
November 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
November 1988, Cancer research,
K H Lee, and M Talpaz, and J M Rothberg, and J L Murray, and N Papadopoulos, and C Plager, and R Benjamin, and D Levitt, and J Gutterman
October 1991, Journal of the National Cancer Institute,
Copied contents to your clipboard!